180 Life Sciences Corp. (ATNF)
2025-06-30 | ||||
|---|---|---|---|---|
| Foreign currency translation adjustments | 143,435 | |||
| Deemed dividend | - | |||
| Income tax benefit | - | |||
| Research and development | 182,386 | |||
| Research and development - related parties | 140,372 | |||
| General and administrative | 1,407,657 | |||
| Total operating expenses | 1,730,415 | |||
| Loss from operations | -1,730,415 | |||
| Other income | 6,483 | |||
| Interest expense | 2,672 | |||
| Change in fair value of derivative liabilities | - | |||
| Gain on settlement of liabilities | - | |||
| Total other (expense) income, net | 3,811 | |||
| Income (loss) before income taxes | -1,726,604 | |||
| Net income (loss) | -1,726,604 | |||
| Net income (loss) available to common stockholders | -1,726,604 | |||
| Total comprehensive loss | -1,870,039 | |||
| Basic (in dollars per share) | -0.3 | |||
| Basic (in shares) | 5,708,126 | |||
| Diluted (in dollars per share) | -0.3 | |||
| Diluted (in shares) | 5,708,126 | |||